107 related articles for article (PubMed ID: 27396030)
21. Estimating the cost of new drug development: is it really 802 million dollars?
Adams CP; Brantner VV
Health Aff (Millwood); 2006; 25(2):420-8. PubMed ID: 16522582
[TBL] [Abstract][Full Text] [Related]
22. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. A proposal for a new authority category.
Glasziou PP
Med J Aust; 1995 Jan; 162(1):33-6. PubMed ID: 7605432
[TBL] [Abstract][Full Text] [Related]
23. [Assessment of novel antidiabetic drugs in Germany. Do innovations still have a chance?].
Gallwitz B
MMW Fortschr Med; 2014 Jul; 156(13):57-60. PubMed ID: 25318228
[No Abstract] [Full Text] [Related]
24. Support for trials of promising medications through the Pharmaceutical Benefits Scheme.
Bell KD
Med J Aust; 1995 Apr; 162(8):447; author reply 447-8. PubMed ID: 7746194
[No Abstract] [Full Text] [Related]
25. Lilly pays $50 million for Korean BTK.
Proffitt A
Nat Biotechnol; 2015 May; 33(5):440. PubMed ID: 25965740
[No Abstract] [Full Text] [Related]
26. [Grave diarrhea associated with idelalisib administration].
Suárez Del Olmo D; Corregidor Luna L; Hidalgo Correas FJ; García Benayas E; García Díaz B
Farm Hosp; 2016 May; 40(3):227-9. PubMed ID: 27145392
[No Abstract] [Full Text] [Related]
27. New estimates of drug development costs.
Frank RG
J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149
[No Abstract] [Full Text] [Related]
28. How some patients in new-drug trials can get cut off.
Anand G
Wall St J (East Ed); 2003 Dec; ():A1, A11. PubMed ID: 14971381
[No Abstract] [Full Text] [Related]
29. IPI-145 shows promise in CLL patients.
Cancer Discov; 2014 Feb; 4(2):136. PubMed ID: 24501284
[TBL] [Abstract][Full Text] [Related]
30. Costing drug development.
Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
[No Abstract] [Full Text] [Related]
31. Idelalisib has activity in mantle cell lymphoma.
Cancer Discov; 2014 May; 4(5):OF8. PubMed ID: 24795031
[TBL] [Abstract][Full Text] [Related]
32. More Chinese get free drugs in clinical trials.
Berton E
Wall St J (East Ed); 2006 Feb; ():B1, B8. PubMed ID: 16528877
[No Abstract] [Full Text] [Related]
33. Pharmaceutical manufacturers seek OIG comfort.
Becker S
Health Care Law Mon; 2002 Aug; ():3-6. PubMed ID: 12420396
[No Abstract] [Full Text] [Related]
34. Epilogue: New drugs for neglected diseases.
Pogge T; Hollis A
Camb Q Healthc Ethics; 2011 Apr; 20(2):329-34. PubMed ID: 21435308
[No Abstract] [Full Text] [Related]
35. Application of drug metabolism and pharmacokinetics for new drug development.
Kim YG; Kang KW
Arch Pharm Res; 2011 Nov; 34(11):1769-71. PubMed ID: 22139678
[No Abstract] [Full Text] [Related]
36. Institute of Medicine, Congress seek solutions to FDA's safety woes through reform, funding.
Finkelstein JB
J Natl Cancer Inst; 2007 Jan; 99(2):104-7. PubMed ID: 17227990
[No Abstract] [Full Text] [Related]
37. JAK2 inhibition for the treatment of hematologic and solid malignancies.
Harry BL; Eckhardt SG; Jimeno A
Expert Opin Investig Drugs; 2012 May; 21(5):637-55. PubMed ID: 22493978
[TBL] [Abstract][Full Text] [Related]
38. The year's new drugs.
Graul AI; Prous JR
Drug News Perspect; 2005; 18(1):21-36. PubMed ID: 15753973
[TBL] [Abstract][Full Text] [Related]
39. Transient hypophysitis in a patient treated by duvelisib for chronic lymphocytic leukemia.
Orioli L; Sarti K; Van Den Neste E; Maiter D
Ann Hematol; 2017 Apr; 96(4):685-686. PubMed ID: 28150013
[No Abstract] [Full Text] [Related]
40. Polo-like kinase inhibitors in hematologic malignancies.
Talati C; Griffiths EA; Wetzler M; Wang ES
Crit Rev Oncol Hematol; 2016 Feb; 98():200-10. PubMed ID: 26597019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
